Company Profile
MediciNova, Inc., a biopharmaceutical company focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.
It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma
Prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and metabolic disorders Including nonalcoholic fatty liver disease and hypertriglycedemia. Incorporated in 2000, MediciNova is headquartered in La Jolla, California.